Introduction
Cancer is a worldwide health problem, representing the leading cause of mortality and morbidity worldwide and accounting for 13% (8.2 million) of all human deaths in 2012 as indicated by the WHO. Although there are more than 100 types of cancer, the main types of cancer leading to death are lung cancer (1.4 million, 18.4%), gastric cancer (0.866 million, 11.4%), liver cancer (0.653 million, 8.6%), colon cancer (0.677 million, 8.9%), and breast cancer (0.548 million, 7.2%). It was estimated that the number of deaths attributed to cancer would rise to an annual 19.3 million by 2025. 1−4 For this reason, the search for new cancer-treating agent is an important research area in both organic and medicinal chemistry. Many chemical substances having heterocyclic units have been synthesized and evaluated as anticancer drug candidates in recent years. Among the heterocyclic compounds, benzimidazole is an important pharmacophore and has a privileged structure in drug discovery.
Many benzimidazole derivatives possess a variety of biological properties such as antiulcer, 5 antihypertensive, 6 antiviral, 7 antihelmentic, 8 antifungal, 9 antibacterial, 10 and antitubercular agents, 11 and several other kinds of therapeutic agent that are still under investigation for their antitumor properties. 5−18 In the literature, various benzimidazole derivatives showed remarkable and promising antitumor properties. 12−26 We have also synthesized and investigated in vitro and in vivo the antibacterial properties of many benzimidazole derivatives for the past two decades and obtained promising results. 27−34 These results encouraged us to synthesize new benzimidazole derivatives and investigate their potential antitumor properties in order to find an effective drug candidate against cancer.
Results and discussion

Synthesis
The compounds 1-3 were synthesized from the nucleophilic substitution reaction of 1-[2-(4-methoxyphenyl)ethy] lbenzimidazole (I) with 2-phenylethyl bromide, penthyl bromide, and allyl bromide, respectively. The compounds 4-7 were synthesized from the nucleophilic substitution reaction of 1-(phthalimide-2-yl)methylbenzimidazole (II) with 2-phenylethyl bromide, 4-nitrobenzyl chloride, penthyl bromide, and allyl bromide, respectively.
These compounds were characterized by elemental analysis and FT-IR, 1 H NMR, and 13 C NMR spectroscopy.
The general synthesis scheme of the compounds is shown in the Scheme.
FT-IR spectroscopy
Characteristic ν (C=N ) bands of the benzimidazolium salts (1-7) in the infrared spectrum were observed between 1560 and 1564 cm −1 . In the IR spectra of 4-7, C=O stretching vibrations were observed between 1718 and 1724 cm −1 .
NMR spectroscopy
The benzimidazolium salts are air-and moisture-stable both in the solid state and in solution. The new benzimidazole derivatives (1-7) were characterized by 1 H and 13 C NMR, which supported the proposed structures. The NCHN proton signals for the benzimidazolium salts 1-7 were observed as singlets at 9.73, 9.71, 9.67, 9.86, 10.18, 9.93, and 9.89 ppm, respectively. As expected, the highest shift to downfield of the NCHN proton signals was observed at the bearing electron withdrawing nitro substituent of compound 5.
These chemical shift values are also parallel to the acidity of the compounds. 
In vitro anticancer activity
The percentages of changes in viability in PC-3 cells after treatment for 24 and 48 h of 1, 5, 25, 50, and 100 µ M concentrations of benzimidazole derivatives are shown in Tables 1 and 2 , respectively. As can be seen from Tables 1 and 2 , the benzimidazole compounds containing a 2-(4-methoxyphenyl)ethyl group (1-3) exhibit antitumor activity on A2780 cell lines at all tested concentrations except 1 µ M (P < 0.05).
The benzimidazole compounds containing (phthalimide-2-yl)methyl substituent (4-7) have antitumor activity on A2780 cell lines at all tested concentrations, except at 1 µ M for compound 5 (P < 0.05). Compared to antitumor activity on A2780 with chemical structures, compounds containing 2-(4-methoxyphenyl)ethyl substituent were more active than the others (4-7) when the results for both 24 and 48 h are taken into consideration. The high activity of these group benzimidazole compounds may result from the phenylethylnitrogen skeleton structurally related to hordanine moiety. When compared to the results obtained from a 24-h treatment, stronger cytotoxic activity is observed for the benzimidazole derivatives after a 48-h treatment. The effects of benzimidazole derivatives of 1, 5, 25, 50, and 100 µ M concentrations on PC-3 cell viability after a 24-h treatment are given as percentage values in Table 3 and after a 48-h treatment in Table 4 . When compared to the results obtained from 24-h and 48-h treatments, similar cytotoxic activity is observed for all benzimidazole derivatives (1-7) against PC-3 cell lines at 25, 50, and 100 µ M, except compound 6, which shows antitumor activity only 50 and 100 µM after 24-h treatment. Similar to the result of the A2780 cell lines, the benzimidazol compounds bearing a 2-(4-methoxyphenyl) ethyl group generally exhibit better antitumor activity on PC-3 cell lines than the others (Table 3, compounds 1, 2, and 3) (P < 0.05). A time-dependent cell viability assay for the tested benzimidazole compounds (1-7) was conducted and their LogIC 50 values were calculated after 24-and 48-h treatments. The results are given in Table 5 . 
Conclusions
In the present study, new salt-type benzimidazole derivatives having phenylethyl, (4-methoxyphenyl)ethyl, penthyl, allyl, phthalimide-2-ylmethyl, and 4-nitrophenyl substituents at the nitrogen atoms of the imidazole ring were synthesized. They were characterized by 1 H NMR, 13 C NMR, IR, and microanalysis. Anticancer properties of these compounds were investigated by [3-(4,5-dimethylthiazole)-2-yl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Our results indicate that the new benzimidazole derivatives display potential anticancer activities against ovarian (A2780) and prostate (PC-3) cancer cell lines (P < 0.05). Compounds 1, 2, and 3 are the most promising compounds in this series and they show high antitumor activity in both cancer cell lines (Figures 1 and 2, compounds 1, 2, and 3 ).
Experimental
Materials and methods
The starting materials and reagents used in the reactions were supplied commercially by Aldrich, Acros, ABCR, and Merck. Scheme. Synthesis of the benzimidazole derivatives.
Synthesis of benzimidazolium salts
1-[2-(4-Methoxyphenyl)ethyl]benzimidazole (I) and 1-(phthalimide-2-yl)methylbenzimidazole (II) used in this
work as starting compounds were prepared by treating benzimidazole and 2-(4-methoxyphenyl)ethyl chloride and (phthalimide-2-yl)methyl chloride, respectively, similar to the literature procedure.
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General method for the synthesis of compounds 1-3
Equivalent amount of the 1-[2-(4-methoxyphenyl)ethyl]benzimidazole (I) and appropriate alkyl halide were refluxed in dimethylformamide (3 mL) for 5 h. Then the mixture was cooled to room temperature and the volatiles were removed under reduced pressure. The residue was crystallized from ethanol/diethyl ether (1:5). 
Synthesis of 1-[2-(4-methoxyphenyl)ethyl]-3-phenylethylbenzimidazolium bromide (1)
Yield
Synthesis of 1-[2-(4-methoxyphenyl)ethyl]-3-penthylbenzimidazolium bromide (2)
Yield, 
General method for the synthesis of compounds 4-7
Equivalent amount of the 1-(phthalimide-2-yl)methylbenzimidazole (II) and appropriate alkyl halide were refluxed in dimethylforamide (3 mL) for 5 h. Then the mixture was cooled to room temperature and the volatiles were removed with reduced pressure. The residue was crystallized from ethanol/diethyl ether (1:5). 
1-Phenylethyl-3-(phthalimide-2-yl)methylbenzimidazolium bromide (4)
C 6 H 5 ), 48.2 (NCH 2 N), 47.5 (CH 2 CH 2 C 6 H 5 ), 35.2 (CH 2 CH 2 C 6 H 5 ).
1-(4-Nitrobenzyl)-3-(phthalimide-2-yl)methylbenzimidazolium chloride (5).
Yield 
Cell cultures
A2780 and PC-3 cell lines were preserved in RPMI-1640 culture medium supplemented with L-glutamine (10% heat-inactivated fetal bovine serum, 100 U/mL penicillin-streptomycin), with addition of 10 mM nonessential amino acids for culture of prostate cancer cells. The cell lines were kept at 37
• C in a 5% CO 2 humidified incubator.
MTT assay
The synthesized benzimidazole compounds were screened for their antitumor activities against different type cancer cell lines (PC-3 and A2780) by MTT assay. The pale yellow tetrazolium salt, MTT, was transformed by active mitochondria to form a dark blue formazan that was determined by a microplate reader.
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The MTT method provides a simple way to detect living and growing cells without using radioactivity.
Shortly, 15 × 10 3 prostate and ovarian cancer cells were plated in triplicate in 96-well flat bottom tissue culture plates, and treated with DMSO (for positive control group) and different concentrations (1, 5, 25, 50 , and 100 µ M) of benzimidazole compounds (1-7) in DMSO; then cells were incubated for 24 and 48 h at 37
• C in a 5% CO 2 humidified incubator. After 24 and 48 h MTT (0.005 g/mL in phosphate buffer saline) was added to the cell culture and incubated for 3 h. The formazan crystals formed during the reaction of active mitochondria with MTT were dissolved in 0.04 N (100 mL) isopropanol and readings were recorded on a microplate reader using a 570 nm filter. The relative cell viability (%) was expressed as a percentage relative to the untreated control cells. Each value represented an average of 10 measurements. All cellular results were determined against control cells.
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Statistical analyses
Quantitative data were presented as mean ± standard deviation (SD). Normal distribution was confirmed by Kolmogorov-Smirnov test. Quantitative data were analyzed using Kruskal-Wallis H test following the MannWhitney U test with Bonferroni adjustment as a post-hoc test.
All P values < 0.05 were considered statistically significant. All analyses were done by IBM SPSS Statistics 22.0 for Windows. The LogIC 50 values were determined by using % cell viability values of compounds by the GraphPad Prism 6 program. 
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